This website uses cookies to ensure you get the best experience. By continuing to browse the site, you agree to our use of cookies.

March Investment Report 2024

Biggest Seed, Series A-E and Venture Investments within Oncology March 2024.

View the report at the bottom of this page.

March 2024 Snapshot:

174 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 2,663,715,585 total true investment received in USA and EU within the Oncology sector in March 2024 across 40 different biotechs.

Some Notable True Oncology Investments

✅Clasp Therapeutics - $150,000,000 (Series A): Pioneer precision immuno-oncology using next-generation T Cell engagers

✅Edgewood Oncology - $ 20,000,000 (Series A): Advancement of lead program in patients with hematologic malignancies and genetically-defined solid tumors 

✅FogPharma - $ 145,000,000 (Series E): ongoing clinical development of the company’s first-in-class intracellular TCF-blocking β-catenin inhibitor in Phase ½ trial in solid tumors

✅Rakuten Medical - $ 119,000,000 (Series E): Further develop its proprietary platform, approval of 1x candidate, and support of its multiple programs

✅Capstan Therapeutics - $ 175,000,000 (Series B): advance its lead program in vivo chimeric antigen receptor T cell (CAR-T) candidate, early clinical proof-of-concept in autoimmune disorders, and further develop tLNP pipeline

✅ Plus 30+ companies in the report.

Click here to view the full report.

Subscribe and recieve exclusive bonuses, tips and resources
Last name
Thank you! You've now subscribed to our mailing list. You'll receive exclusive bonuses, tips and resources directly to your inbox.
Oops! Something went wrong while submitting the form.